Abstract
Galectin-3 is a prognostic heart failure biomarker associated with aldosterone-induced myocardial fibrosis; mineralocorticoid receptor antagonists (MRAs) may reduce such fibrosis. We sought to examine outcomes of patients with heart failure with reduced ejection fraction (HFrEF) as a function of galectin-3 and MRA therapy. A total of 151 patients with chronic HFrEF were categorized by baseline galectin-3 and subsequent MRA therapy trends with regard to cardiovascular (CV) events, left ventricular remodeling, safety, and quality of life, over a mean of 10 months. Although galectin-3 >20 ng/mL was associated with doubling in adjusted risk for CV events, regardless of MRA treatment, there was no difference in CV event rates with regard to MRA use patterns, independent of galectin-3 concentrations. Specifically, in patients with elevated galectin-3 treated with intensified MRA therapy, a significant difference was not detected in CV event rates (P = .79) or the cumulative number of such events (P = .76). Adjusted analysis revealed no difference in time to first CV event if MRA was added/intensified in those with elevated galectin-3 (hazard ratio 0.99, 95% CI 0.97-1.02, P = .74); similarly, cumulative MRA dose was not a specific pre...Continue Reading
References
Nov 3, 2004·Circulation·Umesh C SharmaYigal M Pinto
Sep 19, 2006·Journal of the American College of Cardiology·Roland R van KimmenadeYigal M Pinto
May 26, 2009·American Heart Journal·Robin A P WeirHenry J Dargie
Apr 7, 2010·American Heart Journal·Anju BhardwajJames L Januzzi
Nov 16, 2010·The New England Journal of Medicine·Faiez ZannadUNKNOWN EMPHASIS-HF Study Group
Dec 30, 2010·Annals of Medicine·Rudolf A de BoerDirk J van Veldhuisen
May 24, 2011·The American Journal of Cardiology·W H Wilson TangAllan L Klein
Oct 22, 2011·Circulation. Heart Failure·G Michael FelkerChristopher M O'Connor
Oct 25, 2011·Journal of the American College of Cardiology·James L JanuzziMarc J Semigran
May 15, 2013·European Journal of Heart Failure·Shweta R MotiwalaJames L Januzzi
Jun 7, 2013·Circulation·UNKNOWN WRITING COMMITTEE MEMBERSUNKNOWN American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Oct 12, 2013·Circulation. Heart Failure·Hanna K GagginJames L Januzzi
Dec 7, 2013·Journal of Cardiac Failure·Mona FiuzatChristopher M O'Connor
Mar 14, 2014·JACC. Heart Failure·Hanna K GagginJames L Januzzi
Apr 26, 2014·Future Cardiology·Yang XueW Frank Peacock
May 3, 2014·Cardiovascular Drugs and Therapy·Rudolf A de BoerAlan Maisel
Aug 19, 2014·The American Journal of Cardiology·Alan MaiselRudolf A de Boer
Dec 3, 2014·Clinica Chimica Acta; International Journal of Clinical Chemistry·Mando D FilipeRudolf A de Boer
Citations
Aug 6, 2015·Seminars in Dialysis·Samantha Dias Suthar, John P Middleton
Aug 19, 2015·Current Heart Failure Reports·Parul U GandhiTariq Ahmad
Apr 14, 2016·Clinica Chimica Acta; International Journal of Clinical Chemistry·Matteo BeltramiAlberto Palazzuoli
Oct 22, 2016·Autoimmunity Reviews·Francesca SacconAndrea Doria
Oct 21, 2016·Current Heart Failure Reports·Shweta R Motiwala, Hanna K Gaggin
Jul 29, 2016·Heart·Giuseppe Di TanoSalvatore Pirelli
Apr 14, 2017·Journal of Hypertension·T N A Daniëlle van den BergNiels P Riksen
Sep 2, 2016·Circulation. Heart Failure·Nasrien E IbrahimJames L Januzzi
Aug 25, 2017·Nature Reviews. Disease Primers·Michelle W BloomJaved Butler
Sep 29, 2019·Acta Cardiologica·Manon BarutautPhilippe Rouet
Jun 25, 2020·Journal of the American Heart Association·Sri Lekha TummalapalliUNKNOWN CRIC Study Investigators †
Feb 17, 2017·Current Heart Failure Reports·Vichai SenthongW H Wilson Tang
May 19, 2020·The American Journal of Cardiology·Martin Robert GrüblerWinfried März
Sep 10, 2021·European Journal of Heart Failure·Wouter C MeijersRudolf A de Boer